Biological Age: The New Frontier in Cancer Immunotherapy

BINYAMINA, Israel & CARY, NC – April 15, 2026 – A groundbreaking study is poised to challenge the conventional, tumor-focused approach to cancer treatment by looking at a more fundamental factor: a patient's biological age. OncoHost, a technology company specializing in precision oncology, announced it will present new research at the American Association for Cancer Research (AACR) Annual Meeting 2026, detailing how protein-based biomarkers that measure biological aging can predict a patient's response to immunotherapy.

The findings suggest that the key to unlocking more effective cancer care may lie not just within the tumor itself, but in the systemic health and age of the patient's entire body, particularly the immune system. This holistic view could usher in a new era of personalized medicine, offering clinicians a powerful tool to guide life-saving treatment decisions.

Beyond the Tumor: A Systemic View of Cancer

For decades, oncology has largely been "tumor-centric," focusing on the genetic mutations and characteristics of the cancer cells. While this has led to significant advances, it often overlooks the complex interplay between the tumor and the patient's own body—the "host." OncoHost's research represents a significant paradigm shift, moving the focus from the "seed" (the tumor) to the "soil" (the patient's biological environment).

The company utilizes proteomics, the large-scale study of proteins, to create a dynamic snapshot of a patient's health. Unlike genomics, which provides a static genetic blueprint, proteomics captures the real-time activity of proteins, which are the functional workhorses of cells. By analyzing thousands of proteins in a single blood sample, researchers can build models that calculate a person's "biological age"—a more accurate measure of health and aging than chronological age.

"This research expands our understanding of how systemic and organ-specific aging processes influence cancer biology and response to immunotherapy," said Michal Harel, Ph.D., VP Translational Medicine at OncoHost and the study's lead author, in a statement. "By capturing both systemic biological aging and organ-specific aging across multiple tissues, we are uncovering clinically relevant signals that go beyond traditional biomarkers."

The 'Age Gap' That Predicts Survival

The study, titled "Proteomic aging biomarkers predict survival in immunotherapy-treated tumors," analyzed the plasma proteomic profiles of patients with metastatic solid tumors—including non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), renal cell carcinoma (RCC), and melanoma.

The results were striking. Cancer patients were found to have a significantly higher biological age compared to healthy individuals of the same chronological age. This "age gap" was also organ-specific; for instance, patients with lung cancer showed accelerated aging in their lungs, while those with kidney cancer exhibited a higher kidney age gap.

Most critically, the research established a direct link between the biological age of the immune system and the effectiveness of immune checkpoint inhibitors, a leading class of immunotherapy drugs. Patients with a "high immune age gap"—meaning their immune system was biologically older and less robust—had significantly shorter overall survival rates when treated with immunotherapy compared to those with a low immune age gap. The median overall survival was just 16.4 months for the high-gap group, versus 31.8 months for the low-gap group.

This prognostic power varied by cancer type, showing the strongest effect in melanoma, a cancer known for its responsiveness to immunotherapy, and no significant effect in SCLC, which is often less immunogenic. This suggests the biomarker could help clinicians stratify patients and tailor treatments based on the specific interplay between the tumor type and the patient's host biology.

From Research to Clinical Reality with PROphet®

These findings are not merely academic; they are being translated into a tangible clinical tool through OncoHost's proprietary platform, PROphet®. This AI-driven, plasma-based test analyzes patterns in approximately 7,000 proteins from a single pre-treatment blood sample to guide therapy decisions.

The company's first commercial product, PROphetNSCLC®, is already providing guidance for patients with non-small cell lung cancer. The test helps oncologists decide whether immunotherapy alone or a combination with chemotherapy is the optimal first-line treatment for a specific patient. This level of precision is critical, as it can help avoid ineffective treatments and their associated toxicities and costs. The PROphetic clinical trial, which has enrolled over 1,700 patients globally, provides the robust data needed to validate and refine the platform's predictive algorithms.

The new research on biological aging adds another powerful layer to the PROphet® platform's capabilities, promising to expand its utility across a wider range of cancers and treatment scenarios. The ability to assess the health of the immune system before starting treatment addresses one of the greatest unmet needs in oncology: better predictive biomarkers for immunotherapy.

"Being selected to present at AACR highlights the power of moving beyond tumor-centric thinking," said Ofer Sharon, MD, CEO of OncoHost. "By quantifying biological aging across the body, and specifically the immune system, we are uncovering a new layer of insight into cancer progression and treatment response."

Charting the Future of Precision Diagnostics

OncoHost's innovation comes at a time when the precision oncology market is rapidly expanding, with a projected value exceeding $200 billion by the end of the decade. The field is crowded with companies developing liquid biopsies and genomic tests, but OncoHost's focus on proteomics and biological aging provides a unique and potentially disruptive approach.

Competitors like Caris Life Sciences are also integrating proteomics with other 'omics' data, while companies like Biodesix have their own proteomic tests for NSCLC. However, the concept of an "immune age gap" as a predictive biomarker is a novel differentiator that could give OncoHost a significant edge.

The path from a research poster to a standard-of-care diagnostic is challenging, involving rigorous regulatory hurdles with bodies like the FDA and complex reimbursement negotiations with payers. Yet, the clear clinical need for better biomarkers, coupled with the ease of a simple blood test, positions the technology for strong clinical adoption. By providing a more complete picture of the patient, this new approach has the potential to make immunotherapy more predictable and effective, ultimately transforming treatment strategies and improving outcomes for cancer patients worldwide.